Covered recipient · General Payments record
LEE S SCHWARTZBERG
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$139,658.26
154 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $64,590.00 | 41 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $60,875.00 | 16 |
| Travel and Lodging | $8,123.79 | 24 |
| Food and Beverage | $3,200.78 | 58 |
| Education | $1,863.73 | 2 |
| Long term medical supply or device loan | $999.96 | 12 |
| Honoraria | $5.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $54,353.62 | 38 |
| Daiichi Sankyo Inc. | $43,212.43 | 51 |
| Napo Pharmaceuticals Inc | $12,077.10 | 5 |
| Cornerstone Specialty Network LLC | $10,376.00 | 10 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $6,008.27 | 18 |
| Merck Sharp & Dohme LLC | $5,750.08 | 6 |
| Alexion Pharmaceuticals, Inc. | $2,460.00 | 1 |
| AstraZeneca UK Limited | $2,055.00 | 1 |
| E.R. Squibb & Sons, L.L.C. | $1,791.00 | 1 |
| Siemens Medical Solutions USA, Inc. | $1,000.00 | 1 |
| Janssen Biotech, Inc. | $132.08 | 5 |
| PFIZER INC. | $123.71 | 7 |
| SEAGEN INC. | $72.73 | 1 |
| ARRAY BIOPHARMA INC | $56.19 | 2 |
| Astellas Pharma US Inc | $51.08 | 2 |
| SOBI, INC | $48.26 | 1 |
| Ipsen Biopharmaceuticals, Inc | $47.42 | 2 |
| Incyte Corporation | $27.61 | 1 |
| Lilly USA, LLC | $15.68 | 1 |
Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LEE S SCHWARTZBERG
NPI 1306878228 · CMS profile ID 285831
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
RENO, NV
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1306878228?year=2024&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LEE S SCHWARTZBERG, NPI 1306878228, CMS profile ID 285831. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306878228?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). LEE S SCHWARTZBERG, NPI 1306878228, CMS profile ID 285831. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306878228?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- LEE S SCHWARTZBERG, NPI 1306878228, CMS profile ID 285831, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1306878228?year=2024&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
154 matching records · $139,658.26 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–154 of 154.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc. | $650.00 | 01/07/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089480041 | CMS |
| Daiichi Sankyo Inc. | $650.00 | 01/07/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089480043 | CMS |
| AstraZeneca Pharmaceuticals LP | $701.69 | 01/06/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105455249 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,370.00 | 01/05/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104688658 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $125.00 | 1 |
| PY2025 | Principal investigator | $1,198,519.86 | 77 |
| PY2024 | Recipient | $11,678.86 | 5 |
| PY2024 | Principal investigator | $1,036,057.75 | 78 |
| PY2023 | Recipient | $9,937.71 | 1 |
| PY2023 | Principal investigator | $349,635.90 | 29 |
| PY2022 | Recipient | $3,195.65 | 5 |
| PY2022 | Principal investigator | $209,745.03 | 11 |
| PY2021 | Recipient | $11,105.61 | 9 |
| PY2021 | Principal investigator | $1,170,134.05 | 40 |
| PY2020 | Recipient | $11,505.17 | 11 |
| PY2020 | Principal investigator | $1,710,287.78 | 70 |
| PY2019 | Recipient | $21,967.49 | 5 |
| PY2019 | Principal investigator | $182,904.88 | 62 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
78 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $86,640.20 | 12/31/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in Participants With Previously Untr | No dispute reported | 06/30/2026 | 1232923122 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $60,253.28 | 12/31/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT Sacituzumab Tirumotecan, MK-2870 Followed by Carboplatin,Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Earl | No dispute reported | 06/30/2026 | 1232925115 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $28,009.77 | 12/31/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E | No dispute reported | 06/30/2026 | 1232934764 |
| Principal investigator 1 | PFIZER INC. | $6,568.80 | 12/31/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228733615 |
| Principal investigator 1 | PFIZER INC. | $3,154.20 | 12/29/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716759 |
| Principal investigator 1 | PFIZER INC. | $18,384.10 | 12/27/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228725276 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $85,728.00 | 12/15/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E | No dispute reported | 06/30/2026 | 1232934762 |
| Principal investigator 1 | PFIZER INC. | $2,189.60 | 12/13/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228746985 |
| Principal investigator 1 | PFIZER INC. | $2,102.80 | 12/09/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716757 |
| Recipient | Hoffmann-La Roche Limited | $125.00 | 12/08/2025 | Covered Recipient Physician | MORPHEUS TNBC | No dispute reported | 06/30/2026 | 1211537348 |
| Principal investigator 1 | PFIZER INC. | $76,400.80 | 12/04/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228711940 |
| Principal investigator 1 | PFIZER INC. | $37.50 | 12/04/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712008 |
| Principal investigator 1 | PFIZER INC. | $27,059.90 | 11/26/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228726832 |
| Principal investigator 1 | PFIZER INC. | $2,102.80 | 11/04/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716933 |
| Principal investigator 1 | PFIZER INC. | $7,617.40 | 10/31/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228730649 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $42,691.19 | 10/28/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190297816 |
| Principal investigator 1 | PFIZER INC. | $30.00 | 10/17/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712126 |
| Principal investigator 1 | PFIZER INC. | $468.45 | 10/14/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228712520 |
| Principal investigator 1 | PFIZER INC. | $2,102.80 | 10/13/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716663 |
| Principal investigator 1 | PFIZER INC. | $4,697.00 | 10/09/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228742026 |
| Principal investigator 1 | PFIZER INC. | $3,556.00 | 09/24/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228758438 |
| Principal investigator 1 | PFIZER INC. | $22.50 | 09/18/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228711942 |
| Principal investigator 1 | PFIZER INC. | $57,300.60 | 09/18/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712128 |
| Principal investigator 1 | PFIZER INC. | $95,501.00 | 09/09/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228711826 |
| Principal investigator 1 | PFIZER INC. | $30.00 | 09/09/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712006 |
| Principal investigator 1 | PFIZER INC. | $9,940.00 | 09/09/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228749587 |
| Principal investigator 1 | PFIZER INC. | $2,102.80 | 09/04/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716841 |
| Principal investigator 1 | PFIZER INC. | $6,950.30 | 08/29/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228787738 |
| Principal investigator 1 | Genentech, Inc. | $900.00 | 08/26/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC | No dispute reported | 06/30/2026 | 1211553217 |
| Principal investigator 1 | Genentech, Inc. | $350.00 | 08/21/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211553330 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $10,250.00 | 08/14/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1211553233 |
| Principal investigator 1 | PFIZER INC. | $114,601.20 | 08/12/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228711888 |
| Principal investigator 1 | PFIZER INC. | $30,560.30 | 08/12/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712326 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 08/12/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712518 |
| Principal investigator 1 | PFIZER INC. | $1,048.60 | 08/08/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228767387 |
| Principal investigator 1 | PFIZER INC. | $2,102.80 | 08/04/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228717619 |
| Principal investigator 1 | PFIZER INC. | $22.50 | 08/01/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712392 |
| Principal investigator 1 | PFIZER INC. | $52,240.30 | 07/31/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228789566 |
| Principal investigator 1 | PFIZER INC. | $7,030.80 | 07/16/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228783864 |
| Principal investigator 1 | PFIZER INC. | $2,102.80 | 07/09/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716661 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 07/01/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228711824 |
| Principal investigator 1 | PFIZER INC. | $2,102.80 | 06/04/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228717621 |
| Principal investigator 1 | PFIZER INC. | $2,102.80 | 06/04/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228754376 |
| Principal investigator 1 | PFIZER INC. | $22.50 | 05/30/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228762552 |
| Principal investigator 1 | PFIZER INC. | $16,649.30 | 05/30/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228773258 |
| Principal investigator 1 | PFIZER INC. | $5,560.80 | 05/29/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228771976 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $850.00 | 05/28/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1211553229 |
| Principal investigator 1 | Genentech, Inc. | $1,200.00 | 05/20/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC | No dispute reported | 06/30/2026 | 1211553210 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 05/13/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228755416 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 05/13/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228758753 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 05/12/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228757179 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 05/12/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228759529 |
| Principal investigator 1 | PFIZER INC. | $1,822.00 | 05/12/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228771854 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 05/02/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228720505 |
| Principal investigator 1 | Genentech, Inc. | $248.00 | 04/28/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211553293 |
| Principal investigator 1 | PFIZER INC. | $3,154.20 | 04/28/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716843 |
| Principal investigator 1 | PFIZER INC. | $3,154.20 | 04/28/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228758763 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $2,963.00 | 04/21/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1211553221 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $8,431.91 | 04/21/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1211553225 |
| Principal investigator 1 | PFIZER INC. | $4,082.52 | 04/09/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228760638 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 04/09/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228761687 |
| Principal investigator 1 | PFIZER INC. | $57,300.60 | 04/09/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228762547 |
| Principal investigator 1 | PFIZER INC. | $15,280.15 | 04/09/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228768300 |
| Principal investigator 1 | PFIZER INC. | $12,247.56 | 04/09/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228768306 |
| Principal investigator 1 | Genentech, Inc. | $466.00 | 04/07/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211553267 |
| Principal investigator 1 | Genentech, Inc. | $249.00 | 04/07/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211553277 |
| Principal investigator 1 | Genentech, Inc. | $2,367.00 | 04/07/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211553284 |
| Principal investigator 1 | Genentech, Inc. | $4,500.00 | 04/01/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | RO7247669 PLUS PLATINUM BASED CX VERSUS PEMBROLIZUMAB PLUS PLATINUM BASED CX IN 1L NSCLC Ph2 | No dispute reported | 06/30/2026 | 1211553318 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $44,325.32 | 03/24/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190295351 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 03/20/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC | No dispute reported | 06/30/2026 | 1211553213 |
| Principal investigator 1 | PFIZER INC. | $2,000.00 | 03/04/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228779569 |
| Principal investigator 1 | PFIZER INC. | $1,728.00 | 03/03/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228797830 |
| Principal investigator 1 | Genentech, Inc. | $95.00 | 02/25/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211553270 |
| Principal investigator 1 | Genentech, Inc. | $850.00 | 02/25/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211553289 |
| Principal investigator 1 | Genentech, Inc. | $350.00 | 02/18/2025 | Covered Recipient Teaching Hospital Renown Regional Medical Center | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211553281 |
| Principal investigator 1 | PFIZER INC. | $23,036.00 | 02/05/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228759080 |
| Principal investigator 1 | PFIZER INC. | $17,934.75 | 02/03/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER | No dispute reported | 06/30/2026 | 1228795484 |
| Principal investigator 1 | PFIZER INC. | $162.00 | 01/06/2025 | Covered Recipient Teaching Hospital RENOWN REGIONAL MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228723542 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2025 | Amount invested | $0.00 | 1 |
| PY2025 | Value of interest | $50,000.00 | 1 |
| PY2024 | Amount invested | $0.00 | 1 |
| PY2024 | Value of interest | $50,000.00 | 1 |
| PY2023 | Amount invested | $50,000.00 | 1 |
| PY2023 | Value of interest | $50,000.00 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
3 records · PY2023–2025
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2025 | Cornerstone Specialty Network LLC | $0.00 | $50,000.00 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1176816272 |
| PY2024 | Cornerstone Specialty Network LLC | $0.00 | $50,000.00 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1126328727 |
| PY2023 | Cornerstone Specialty Network LLC | $50,000.00 | $50,000.00 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 987500409 |